Every 10-Q that Beyond Air, Inc. (XAIR) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow XAIR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full XAIR filings page.
Beyond Air, Inc. reported another quarterly loss and highlighted serious liquidity risk for the three months ended June 30, 2026. Revenue was essentially flat at $1.8 million, while cost of revenues was $1.5 million, yielding modest gross profit of $0.2 million. Operating expenses remained high at $6.8 million, driven mainly by selling, general and administrative costs, resulting in a loss from operations of $6.6 million and a net loss attributable to Beyond Air of $7.9 million.
Cash used in operating activities was $4.9 million. Cash, cash equivalents, marketable securities and restricted cash totaled $15.2 million, including $5.4 million of restricted cash, against long-term debt of $22.2 million. Management stated that recurring losses, limited cash resources and expected cash outflows raise substantial doubt about the ability to meet obligations within one year without additional financing. During the quarter the company converted $0.5 million of promissory note principal into equity, exercised 95,000 pre-funded warrants, and completed a 1‑for‑20 reverse stock split. After quarter-end it raised $10.2 million gross in a private placement with attached warrants.
Beyond Air, Inc. reported higher revenue but continuing losses for the quarter ended December 31, 2025. Revenue rose to $2.2 million from $1.1 million a year earlier, driven mainly by LungFit PH lease revenue, yet gross profit was only $0.3 million as costs remained high.
The company posted a quarterly net loss attributable to Beyond Air of $7.3 million, versus $13.0 million a year prior, and a nine‑month net loss of $23.0 million. Operating cash use for the nine months was $13.2 million. As of December 31, 2025, cash, cash equivalents, marketable securities and restricted cash totaled $17.8 million, with an accumulated deficit of $309.3 million and long‑term debt of $22.0 million.
Management states that these factors raise “substantial doubt” about the ability to meet obligations without new capital and concluded additional funding will be required within one year of issuance of these statements. To bolster liquidity, the company issued an $11.5 million secured loan and a $12.0 million secured promissory note in late 2024 and 2025, and completed a $5.0 million private placement on January 16, 2026. Beyond Air also gained a European CE mark for LungFit PH in November 2024 and effected a 1‑for‑20 reverse stock split in July 2025. Shares outstanding were 10,529,344 as of February 10, 2026.
Beyond Air (XAIR) reported Q2 FY2026 results. Revenue was $1.8 million, up from $0.8 million a year ago, but cost of revenues of $2.1 million produced a gross loss of $0.3 million. Operating expenses were $7.4 million, leading to a loss from operations of $7.7 million and a net loss of $8.3 million (basic and diluted loss per share $1.25).
Cash, cash equivalents, marketable securities and restricted cash totaled $10.9 million as of September 30, 2025. The company raised $8.1 million via its ATM program and received $2.9 million from warrant exercises during the six months. Long‑term debt, net, was $10.1 million, and management disclosed that recent results and projected cash outflows raise “substantial doubt” about the ability to meet obligations without additional financing.
The LungFit PH leasing business recognized $1.4 million in revenue in the quarter, and minimum future lease payments contracted total $11.1 million through 2029. Shares outstanding were 8,009,488 as of November 7, 2025; this is a baseline figure, not the amount being offered.
Beyond Air reported operational progress but faces a near-term funding gap. Revenue for the three months ended June 30, 2025 rose to $1.76 million from $0.68 million a year earlier, producing a $156,000 gross profit versus a prior gross loss. Operating losses narrowed to $7.62 million and net loss improved to $8.08 million from $13.06 million, reflecting lower R&D and SG&A spend. The company held $6.63 million of cash, marketable securities and restricted cash at period end but used $4.53 million in operating cash flow during the quarter. Management disclosed substantial doubt about meeting obligations with current resources and stated additional funding will be required within one year. Financing actions during the quarter included $2.4 million net ATM proceeds and a $2.0 million related-party advance; long-term debt outstanding under the Loan Agreement remains $11.5 million (facility terms include a 15% annual interest structure). The company has FDA PMA for LungFit PH and CE mark approval for additional indications, and effected a one-for-twenty reverse stock split with retroactive presentation of prior-period per-share amounts.